ABUS insider filings
Arbutus Biopharma Corp — 46 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-07. Screen ABUS transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 8 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Androski Lindsay — President and CEO, Director | 2 | — | — | 6 |
| Beardsley Robert A — Director | 2 | — | — | 6 |
| Nguyen Tuan — Chief Financial Officer | 2 | — | — | 6 |
| Sawhney Roger — Director | 2 | — | — | 6 |
Recent insider filings — Arbutus Biopharma Corp
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-07 | 4 | Androski Lindsay — President and CEO, Director | Disposition to issuer (D): 24,655 @ $5 | EDGAR |
| 2026-10-07 | 4 | Sawhney Roger — Director | Disposition to issuer (D): 17,142 @ $5 | EDGAR |
| 2026-10-07 | 4 | Nguyen Tuan — Chief Financial Officer | Disposition to issuer (D): 48,081 @ $5 | EDGAR |
| 2026-10-07 | 4 | Beardsley Robert A — Director | Disposition to issuer (D): 17,948 @ $5 | EDGAR |
| 2026-09-23 | 4 | Beardsley Robert A — Director | Option exercise (M): 52,533 @ $3.20 · Option exercise (M): 78,800 @ $4.24 · Tax withholding (F): 99,057 @ $5.07 · Option exercise (M): 52,533 (derivative) @ $0 · Option exercise (M): 78,800 (derivative) @ $0 | EDGAR |
| 2026-09-23 | 4 | Sawhney Roger — Director | Option exercise (M): 52,533 @ $3.34 · Option exercise (M): 78,800 @ $4.24 · Tax withholding (F): 100,508 @ $5.07 · Option exercise (M): 52,533 (derivative) @ $0 · Option exercise (M): 78,800 (derivative) @ $0 | EDGAR |
| 2026-09-23 | 4 | Nguyen Tuan — Chief Financial Officer | Option exercise (M): 265,625 @ $3.49 · Option exercise (M): 27,475 @ $4.39 · Tax withholding (F): 206,637 @ $5.07 · Option exercise (M): 265,625 (derivative) @ $0 · Option exercise (M): 27,475 (derivative) @ $0 | EDGAR |
| 2026-09-23 | 4 | Androski Lindsay — President and CEO, Director | Option exercise (M): 116,408 @ $3.20 · Option exercise (M): 10,456 @ $4.39 · Tax withholding (F): 82,527 @ $5.07 · Option exercise (M): 116,408 (derivative) @ $0 · Option exercise (M): 10,456 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Sawhney Roger — Director | Grant/award (A): 78,800 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Beardsley Robert A — Director | Grant/award (A): 78,800 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Nguyen Tuan — Chief Financial Officer | Grant/award (A): 73,500 @ $0 · Grant/award (A): 188,400 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Androski Lindsay — President and CEO, Director | Grant/award (A): 28,000 @ $0 · Grant/award (A): 71,700 (derivative) @ $0 | EDGAR |
| 2025-08-06 | 4 | Sawhney Roger — Director | Grant/award (A): 157,600 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4/A | Nguyen Tuan — Chief Financial Officer | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2025-03-31 | 4 | Nguyen Tuan — Chief Financial Officer | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4 | Hasija Anuj — Director | Grant/award (A): 157,600 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4 | Androski Lindsay — President and CEO, Director | Grant/award (A): 310,422 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4 | Beardsley Robert A — Director | Grant/award (A): 157,600 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Naftzger J. Christopher — General Counsel and CCO | Grant/award (A): 54,300 @ $0 · Grant/award (A): 220,300 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | McElhaugh Michael J. — Interim President & CEO, Director | Grant/award (A): 177,000 @ $0 · Grant/award (A): 718,800 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Sims Karen — Chief Medical Officer | Grant/award (A): 49,300 @ $0 · Grant/award (A): 200,300 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | HASTINGS DAVID C — Chief Financial Officer | Grant/award (A): 90,100 @ $0 · Grant/award (A): 365,800 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Sims Karen — Chief Medical Officer | Sale (S): 19,348 @ $3.28 | EDGAR |
| 2025-02-05 | 4 | McElhaugh Michael J. — Interim President & CEO, Director | Sale (S): 23,790 @ $3.28 | EDGAR |
| 2025-02-05 | 4 | Naftzger J. Christopher — General Counsel and CCO | Sale (S): 11,333 @ $3.28 | EDGAR |
| 2025-02-05 | 4 | HASTINGS DAVID C — Chief Financial Officer | Sale (S): 22,183 @ $3.28 | EDGAR |
| 2024-08-16 | 4 | MANCHESTER KEITH S — Director | Option exercise (M): 54,915 @ $0.56 · Sale (S): 8,846 @ $3.69 · Option exercise (M): 54,915 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Rewolinski Melissa — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Torti Frank — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Meyers James R — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | MANCHESTER KEITH S — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | BURGESS DANIEL D — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | HENRIQUES RICHARD C JR — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Naftzger J. Christopher — General Counsel and CCO | Grant/award (A): 95,100 @ $0 · Grant/award (A): 380,500 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Sims Karen — Chief Medical Officer | Grant/award (A): 101,000 @ $0 · Sale (S): 4,358 @ $2.31 · Grant/award (A): 403,900 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Sofia Michael J. — Chief Scientific Officer | Grant/award (A): 109,500 @ $0 · Sale (S): 9,982 @ $2.31 · Grant/award (A): 437,800 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | McElhaugh Michael J. — Interim President & CEO, Director | Grant/award (A): 123,800 @ $0 · Sale (S): 10,164 @ $2.31 · Grant/award (A): 495,100 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | HASTINGS DAVID C — Chief Financial Officer | Grant/award (A): 112,500 @ $0 · Sale (S): 9,593 @ $2.31 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2023-07-13 | 4 | Rewolinski Melissa — Director | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2023-07-12 | 4 | Sims Karen — Chief Medical Officer | Grant/award (A): 153,640 (derivative) @ $0 | EDGAR |
| 2023-07-12 | 4 | Naftzger J. Christopher — General Counsel and CCO | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | Torti Frank — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | Meyers James R — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | MANCHESTER KEITH S — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | BURGESS DANIEL D — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | HENRIQUES RICHARD C JR — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Arbutus Biopharma Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ABUS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →